Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall neurontinThe drug Neurontin was FDA approved only as a supplementary treatment for partial seizures when no other treatment options were working. Now, Pfizer, the world’s largest drug company, is the target of lawsuits that are in part due to its drug Neurontin and the improper promotion of it. The FDA sent multiple letters to Pfizer because the agency found the drug Neurontin to be improperly represented. Both in 2001 and 2002, the drug Neurontin raised eyebrows, leading the FDA to warn Pfizer about its’ marketing materials.
In May 2002, the Public Citizen consumer group posted an article on the drug Neurontin titled, “The Illegal Corporate Creation of a Blockbuster Drug”. The article exposed evidence of Pfizer’s illegal promotion of unapproved uses for the drug Neurontin. The company was able to use a loophole in FDA policy to come up with more ways to use the drug Neurontin, greatly expanding a previously small corner of the market in order to turn the drug Neurontin into a blockbuster.
Estimates as high as 90% of the drug Neurontin’s sales are from off-label uses that have fueled it to become an over $1.3 billion per year force. Critics of the FDA point to the drug Neurontin as an example of the seemingly little degree of caution that the agency is able to enforce. The FDA had sent Pfizer warning letters because the agency believed the drug Neurontin was being improperly represented.
Civil suits are currently against Pfizer for the drug Neurontin. Consumers and consumer groups are unhappy with large drug companies that over push their products, such as the drug Neurontin, as government regulators appear to enforce little punishment against powerful firms. Various watchdog groups have been critical of the FDA’s lack of aggressive action to protect consumers and the drug Neurontin is one of the most documented cases of the growing power pharmaceutical companies have to manipulate the market.
The FDA has requested 14 drugmakers to check their study data to see if use of epilepsy drugs results in suicidal behavior or thoughts, giving the drugmakers six months to respond.
Sales of anti-seizure drugs in the U.S. during 2004 were th...
Just weeks after Pfizer and its Warner-Lambert Co. unit were penalized $430 million in federal and state courts for selling Neurontin for purposes that have not yet been FDA approved, the company is again under fire for fraudulent marketing practices. ...
The world''s largest drug manufacturer, Pfizer, Inc., agreed to pay at least $400 million in order to settle civil charges regarding kickbacks to encourage doctors to prescribe the anti-epileptic drug Neurontin for other purposes.
The se...